Home/Filings/3/0000950103-19-017350
3//SEC Filing

ROCHE HOLDINGS INC 3

Accession 0000950103-19-017350

CIK 0001609351other

Filed

Dec 17, 7:00 PM ET

Accepted

Dec 18, 4:59 PM ET

Size

7.2 KB

Accession

0000950103-19-017350

Insider Transaction Report

Form 3
Period: 2019-12-17
Holdings
  • Common Stock

    29,746,673
Holdings
  • Common Stock

    29,746,673
Footnotes (4)
  • [F1]This statement is being filed jointly by Roche Holdings, Inc. ("Holdings") and Roche Holdings, Ltd ("Parent" and, together with Holdings, the "Reporting Persons"). Holdings is a subsidiary of Parent. Additionally, the Reporting Persons understand that certain shareholders of Parent are party to a shareholder pooling agreement with respect to a significant portion of (but not a majority of) the issued shares of Parent.
  • [F2]On February 22, 2019, Holdings and the Issuer entered into a Transaction Agreement (the "Transaction Agreement"), pursuant to which Holdings has consummated a tender offer (the "Tender Offer") to purchase all outstanding shares ("Shares") of common stock of the Issuer.
  • [F3]Holdings is the direct beneficial owner of these Shares. Parent is the indirect beneficial owner of these Shares.
  • [F4]Each Reporting Person disclaims beneficial ownership of the Shares reported in Table I except to the extent of its pecuniary interest therein, if any. Each Reporting Person also disclaims beneficial ownership of any Shares that may be or are beneficially owned by any other person. This Form 3 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any Shares for any purpose, other than as reported in Table I above.

Issuer

Spark Therapeutics, Inc.

CIK 0001609351

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0000904566

Filing Metadata

Form type
3
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:59 PM ET
Size
7.2 KB